From Wikipedia, the free encyclopedia
(Redirected from L-dopa)


l-DOPA
Skeletal formula of L-DOPA
Ball-and-stick model of the zwitterionic form of L-DOPA found in the crystal structure [1]
Clinical data
Pronunciation /ˌɛlˈdoʊpə/, /ˌlɛvoʊˈdoʊpə/
Trade namesLarodopa, Dopar, Inbrija, others
AHFS/ Drugs.com Professional Drug Facts
MedlinePlus a619018
License data
Pregnancy
category
Routes of
administration		 By mouth, intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only (some forms are OTC)
  • EU: Rx-only
Pharmacokinetic data
Bioavailability30%
Metabolism Aromatic-l-amino-acid decarboxylase
Elimination half-life0.75–1.5 hours
Excretion renal 70–80%
Identifiers
  • (S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard ( EPA)
ECHA InfoCard 100.000.405 Edit this at Wikidata
Chemical and physical data
FormulaC9H11NO4
Molar mass197.190 g·mol−1
3D model ( JSmol)
  • O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1
  • InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 checkY
  • Key:WTDRDQBEARUVNC-LURJTMIESA-N checkY
   (verify)

l-DOPA, also known as levodopa and l-3,4-dihydroxyphenylalanine, is made and used as part of the normal biology of some plants [3] and animals, including humans. Humans, as well as a portion of the other animals that utilize l-DOPA, make it via biosynthesis from the amino acid l-tyrosine. l-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. Furthermore, l-DOPA itself mediates neurotrophic factor release by the brain and CNS. [4] [5] In some plant families (of the order Caryophyllales), l-DOPA is the central precursor of a biosynthetic pathway that produces a class of pigments called betalains. [6] l-DOPA can be manufactured and in its pure form is sold as a psychoactive drug with the INN levodopa; trade names include Sinemet, Pharmacopa, Atamet, and Stalevo. As a drug, it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia.

l-DOPA has a counterpart with opposite chirality, d-DOPA. As is true for many molecules, the human body produces only one of these isomers (the l-DOPA form). The enantiomeric purity of l-DOPA may be analyzed by determination of the optical rotation or by chiral thin-layer chromatography. [7]

Medical use

l-DOPA crosses the protective blood–brain barrier, whereas dopamine itself cannot. [8] Thus, l-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease, Parkinsonism, dopamine-responsive dystonia and Parkinson-plus syndrome. The therapeutic efficacy is different for different kinds of symptoms. Bradykinesia and rigidity are the most responsive symptoms while tremors are less responsive to levodopa therapy. Speech, swallowing disorders, postural instability and freezing gait are the least responsive symptoms. [9]

Once l-DOPA has entered the central nervous system, it is converted into dopamine by the enzyme aromatic l-amino acid decarboxylase, also known as DOPA decarboxylase. Pyridoxal phosphate ( vitamin B6) is a required cofactor in this reaction, and may occasionally be administered along with l-DOPA, usually in the form of pyridoxine. Because levodopa bypasses the enzyme tyrosine hydroxylase, the rate-limiting step in dopamine synthesis, it is much more readily converted to dopamine than tyrosine, which is normally the natural precursor for dopamine production.

In humans, conversion of l-DOPA to dopamine does not only occur within the central nervous system. Cells in the peripheral nervous system perform the same task. Thus administering l-DOPA alone will lead to increased dopamine signaling in the periphery as well. Excessive peripheral dopamine signaling is undesirable as it causes many of the adverse side effects seen with sole L-DOPA administration. To bypass these effects, it is standard clinical practice to coadminister (with l-DOPA) a peripheral DOPA decarboxylase inhibitor (DDCI) such as carbidopa (medicines containing carbidopa, either alone or in combination with l-DOPA, are branded as Lodosyn [10] ( Aton Pharma) [11] Sinemet ( Merck Sharp & Dohme Limited), Pharmacopa ( Jazz Pharmaceuticals), Atamet ( UCB), Syndopa and Stalevo ( Orion Corporation) or with a benserazide (combination medicines are branded Madopar or Prolopa), to prevent the peripheral synthesis of dopamine from l-DOPA). However, when consumed as a botanical extract, for example from M pruriens supplements, a peripheral DOPA decarboxylase inhibitor is not present. [3]

Inbrija (previously known as CVT-301) is an inhaled powder formulation of levodopa indicated for the intermittent treatment of "off episodes" in patients with Parkinson's disease currently taking carbidopa/levodopa. [12] It was approved by the United States Food and Drug Administration on December 21, 2018, and is marketed by Acorda Therapeutics. [13]

Coadministration of pyridoxine without a DDCI accelerates the peripheral decarboxylation of l-DOPA to such an extent that it negates the effects of l-DOPA administration, a phenomenon that historically caused great confusion.

In addition, l-DOPA, co-administered with a peripheral DDCI, is efficacious for the short-term treatment of restless leg syndrome. [14]

The two types of response seen with administration of l-DOPA are:

  • The short-duration response is related to the half-life of the drug.
  • The longer-duration response depends on the accumulation of effects over at least two weeks, during which ΔFosB accumulates in nigrostriatal neurons. In the treatment of Parkinson's disease, this response is evident only in early therapy, as the inability of the brain to store dopamine is not yet a concern.

Biological role

Biosynthetic pathways for catecholamines and trace amines in the human brain [15] [16] [17]
The image above contains clickable links
In humans, catecholamines and phenethylaminergic trace amines are derived from the amino acid L-phenylalanine.

l-DOPA is produced from the amino acid l- tyrosine by the enzyme tyrosine hydroxylase. l-DOPA can act as an l-tyrosine mimetic and be incorporated into proteins by mammalian cells in place of L-tyrosine, generating protease-resistant and aggregate-prone proteins in vitro and may contribute to neurotoxicity with chronic l-DOPA administration. [18] It is also the precursor for the monoamine or catecholamine neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). Dopamine is formed by the decarboxylation of l-DOPA by aromatic l-amino acid decarboxylase (AADC).

l-DOPA can be directly metabolized by catechol-O-methyl transferase to 3-O-methyldopa, and then further to vanillactic acid. This metabolic pathway is nonexistent in the healthy body, but becomes important after peripheral l-DOPA administration in patients with Parkinson's disease or in the rare cases of patients with AADC enzyme deficiency. [19]

l-Phenylalanine, l-tyrosine, and l-DOPA are all precursors to the biological pigment melanin. The enzyme tyrosinase catalyzes the oxidation of l-DOPA to the reactive intermediate dopaquinone, which reacts further, eventually leading to melanin oligomers. In addition, tyrosinase can convert tyrosine directly to l-DOPA in the presence of a reducing agent such as ascorbic acid. [20]

Marine adhesion

l-DOPA is a key compound in the formation of marine adhesive proteins, such as those found in mussels. [21] [22] It is believed to be responsible for the water-resistance and rapid curing abilities of these proteins. l-DOPA may also be used to prevent surfaces from fouling by bonding antifouling polymers to a susceptible substrate. [23] The versatile chemistry of L-DOPA can be exploited in nanotechnology. [24] For example, DOPA-containing self-assembling peptides were found to form functional nanostructures, adhesives and gels. [25] [26] [27] [28]

Side effects and adverse reactions

The side effects of l-DOPA may include:

Although many adverse effects are associated with l-DOPA, in particular psychiatric ones, it has fewer than other antiparkinsonian agents, such as anticholinergics and dopamine receptor agonists.

More serious are the effects of chronic l-DOPA administration in the treatment of Parkinson's disease, which include:

Clinicians try to avoid these side effects and adverse reactions by limiting l-DOPA doses as much as possible until absolutely necessary.

The long term use of L-Dopa increases oxidative stress through monoamine oxidase led enzymatic degradation of synthesized dopamine causing neuronal damage and cytotoxicity. The oxidative stress is caused by the formation of reactive oxygen species (H2O2) during the monoamine oxidase led metabolism of dopamine. It is further perpetuated by the richness of Fe2+ ions in striatum via the Fenton reaction and intracellular autooxidation. The increased oxidation can potentially cause mutations in DNA due to the formation of 8-oxoguanine, which is capable of pairing with adenosine during mitosis. [30]

History

In work that earned him a Nobel Prize in 2000, Swedish scientist Arvid Carlsson first showed in the 1950s that administering l-DOPA to animals with drug-induced ( reserpine) Parkinsonian symptoms caused a reduction in the intensity of the animals' symptoms. In 1960/61 Oleh Hornykiewicz, after discovering greatly reduced levels of dopamine in autopsied brains of patients with Parkinson's disease, [31] published together with the neurologist Walther Birkmayer dramatic therapeutic antiparkinson effects of intravenously administered l-DOPA in patients. [32] This treatment was later extended to manganese poisoning and later Parkinsonism by George Cotzias and his coworkers, [33] who used greatly increased oral doses, for which they won the 1969 Lasker Prize. [34] [35] The neurologist Oliver Sacks describes this treatment in human patients with encephalitis lethargica in his 1973 book Awakenings, upon which the 1990 movie of the same name is based. The first study reporting improvements in patients with Parkinson's disease resulting from treatment with L-dopa was published in 1968. [36]

The 2001 Nobel Prize in Chemistry was also related to l-DOPA: the Nobel Committee awarded one-quarter of the prize to William S. Knowles for his work on chirally catalysed hydrogenation reactions, the most noted example of which was used for the synthesis of l-DOPA. [37] [38] [39]

Synthesis of l-DOPA via hydrogenation with C2-symmetric diphosphine.

Research

Age-related macular degeneration

In 2015, a retrospective analysis comparing the incidence of age-related macular degeneration (AMD) between patients taking versus not taking l-DOPA found that the drug delayed onset of AMD by around 8 years. The authors state that significant effects were obtained for both dry and wet AMD. [40][ non-primary source needed]

Role in plants and in the environment

In plants, L-DOPA functions as an allelochemical which inhibits the growth of certain species, and is produced and secreted by a few legume species such as the broad bean Vicia faba and the velvet bean Mucuna pruriens. [41] Its effect is strongly dependent on the pH and the reactivity of iron in the soil. [42]

See also

References

  1. ^ Howard ST, Hursthouse MB, Lehmann CW, Poyner EA (1995). "Experimental and theoretical determination of electronic properties in Ldopa". Acta Crystallogr. B. 51 (3): 328–337. Bibcode: 1995AcCrB..51..328H. doi: 10.1107/S0108768194011407. S2CID  96802274.
  2. ^ a b "Levodopa Use During Pregnancy". Drugs.com. 12 July 2019. Retrieved 27 September 2020.
  3. ^ a b Cohen PA, Avula B, Katragunta K, Khan I (October 2022). "Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database". JAMA Neurology. 79 (10): 1085–1086. doi: 10.1001/jamaneurol.2022.2184. PMC  9361182. PMID  35939305.
  4. ^ Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS (September 2008). "L-DOPA is an endogenous ligand for OA1". PLOS Biology. 6 (9): e236. doi: 10.1371/journal.pbio.0060236. PMC  2553842. PMID  18828673.
  5. ^ Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, et al. (January 2014). "The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii". British Journal of Pharmacology. 171 (2): 403–14. doi: 10.1111/bph.12459. PMC  3904260. PMID  24117106.
  6. ^ Polturak G, Breitel D, Grossman N, Sarrion-Perdigones A, Weithorn E, Pliner M, et al. (2016). "Elucidation of the first committed step in betalain biosynthesis enables the heterologous engineering of betalain pigments in plants". New Phytol. 210 (1): 269–283. doi: 10.1111/nph.13796. PMID  26683006.
  7. ^ Martens J, Günther K, Schickedanz M (1986). "Resolution of Optical Isomers by Thin-Layer Chromatography: Enantiomeric Purity of Methyldopa". Arch. Pharm. 319 (6): 572–574. doi: 10.1002/ardp.19863190618. S2CID  97903386.
  8. ^ Hardebo JE, Owman C (July 1980). "Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface". Annals of Neurology. 8 (1): 1–31. doi: 10.1002/ana.410080102. PMID  6105837. S2CID  22874032.
  9. ^ Ovallath S, Sulthana B (2017). "Levodopa: History and Therapeutic Applications". Annals of Indian Academy of Neurology. 20 (3): 185–189. doi: 10.4103/aian.AIAN_241_17. PMC  5586109. PMID  28904446.
  10. ^ "Medicare D". Medicare. 2014. Retrieved 12 November 2015.
  11. ^ "Lodosyn", Drugs, nd, retrieved 12 November 2012
  12. ^ "Inbrija Prescribing Information" (PDF). Retrieved February 14, 2019.
  13. ^ "Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)". ir.acorda.com. Retrieved 2019-02-14.
  14. ^ Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M, et al. (Cochrane Movement Disorders Group) (February 2011). "Levodopa for restless legs syndrome". The Cochrane Database of Systematic Reviews. 2011 (2): CD005504. doi: 10.1002/14651858.CD005504.pub2. PMC  8889887. PMID  21328278.
  15. ^ Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". Pharmacology & Therapeutics. 125 (3): 363–375. doi: 10.1016/j.pharmthera.2009.11.005. PMID  19948186.
  16. ^ Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". Trends in Pharmacological Sciences. 26 (5): 274–281. doi: 10.1016/j.tips.2005.03.007. PMID  15860375.
  17. ^ Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D". European Journal of Pharmacology. 724: 211–218. doi: 10.1016/j.ejphar.2013.12.025. PMID  24374199.
  18. ^ Rodgers KJ (March 2014). "Non-protein amino acids and neurodegeneration: the enemy within". Experimental Neurology. 253: 192–196. doi: 10.1016/j.expneurol.2013.12.010. PMID  24374297. S2CID  2288729.
  19. ^ Hyland K, Clayton PT (December 1992). "Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology" (PDF). Clinical Chemistry. 38 (12): 2405–10. doi: 10.1093/clinchem/38.12.2405. PMID  1281049. Archived from the original (PDF) on 2011-06-07. Retrieved 2008-10-16.
  20. ^ Ito S, Kato T, Shinpo K, Fujita K (September 1984). "Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine". The Biochemical Journal. 222 (2): 407–11. doi: 10.1042/bj2220407. PMC  1144193. PMID  6433900.
  21. ^ Waite JH, Andersen NH, Jewhurst S, Sun C (2005). "Mussel Adhesion: Finding the Tricks Worth Mimicking". J Adhesion. 81 (3–4): 1–21. doi: 10.1080/00218460590944602. S2CID  136967853.
  22. ^ "Study Reveals Details Of Mussels' Tenacious Bonds". Science Daily. Aug 16, 2006. Retrieved Sep 30, 2013.
  23. ^ "Mussel Adhesive Protein Mimetics". Archived from the original on 2006-05-29.
  24. ^ Giuri D, Ravarino P, Tomasini C (June 2021). "L-Dopa in small peptides: an amazing functionality to form supramolecular materials". Organic & Biomolecular Chemistry. 19 (21): 4622–4636. doi: 10.1039/D1OB00378J. hdl: 11585/840774. PMID  33978030. S2CID  234474122.
  25. ^ Fichman G, Adler-Abramovich L, Manohar S, Mironi-Harpaz I, Guterman T, Seliktar D, et al. (July 2014). "Seamless metallic coating and surface adhesion of self-assembled bioinspired nanostructures based on di-(3,4-dihydroxy-L-phenylalanine) peptide motif". ACS Nano. 8 (7): 7220–7228. doi: 10.1021/nn502240r. PMC  4108209. PMID  24936704.
  26. ^ Fichman G, Guterman T, Adler-Abramovich L, Gazit E (August 2014). "The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies". Nanomaterials. 4 (3): 726–740. doi: 10.3390/nano4030726. PMC  5304689. PMID  28344244.
  27. ^ Fichman G, Andrews C, Patel NL, Schneider JP (October 2021). "Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide". Advanced Materials. 33 (40): e2103677. Bibcode: 2021AdM....3303677F. doi: 10.1002/adma.202103677. PMC  8492546. PMID  34423482.
  28. ^ Maity S, Nir S, Zada T, Reches M (October 2014). "Self-assembly of a tripeptide into a functional coating that resists fouling". Chemical Communications. 50 (76): 11154–11157. doi: 10.1039/C4CC03578J. PMID  25110984.
  29. ^ Merims D, Giladi N (2008). "Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease". Parkinsonism & Related Disorders. 14 (4): 273–80. doi: 10.1016/j.parkreldis.2007.09.007. PMID  17988927.
  30. ^ Dorszewska J, Prendecki M, Lianeri M, Kozubski W (February 2014). "Molecular Effects of L-dopa Therapy in Parkinson's Disease". Current Genomics. 15 (1): 11–7. doi: 10.2174/1389202914666131210213042. PMC  3958954. PMID  24653659.
  31. ^ Ehringer H, Hornykiewicz O (December 1960). "[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]". Klinische Wochenschrift. 38 (24): 1236–9. doi: 10.1007/BF01485901. PMID  13726012. S2CID  32896604.
  32. ^ Birkmayer W, Hornykiewicz O (November 1961). "[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]". Wiener Klinische Wochenschrift. 73: 787–8. PMID  13869404.
  33. ^ Cotzias GC, Papavasiliou PS, Gellene R (July 1969). "L-dopa in parkinson's syndrome". The New England Journal of Medicine. 281 (5): 272. doi: 10.1056/NEJM196907312810518. PMID  5791298.
  34. ^ "Lasker Award". 1969. Archived from the original on 2016-01-05., accessed April 1, 2013
  35. ^ Simuni T, Hurtig H (2008). "Levadopa: A Pharmacologic Miracle Four Decades Later". In Factor SA, Weiner WJ (eds.). Parkinson's Disease: Diagnosis and Clinical Management. Demos Medical Publishing. ISBN  978-1-934559-87-1 – via Google eBook.
  36. ^ Cotzias GC (March 1968). "L-Dopa for Parkinsonism". The New England Journal of Medicine. 278 (11): 630. doi: 10.1056/nejm196803142781127. PMID  5637779.
  37. ^ Knowles WS (1983). "Asymmetric hydrogenation". Accounts of Chemical Research. 16 (3): 106–112. doi: 10.1021/ar00087a006.
  38. ^ "Synthetic scheme for total synthesis of DOPA, L- (Monsanto)". UW Madison, Department of Chemistry. Retrieved Sep 30, 2013.
  39. ^ Knowles WS (March 1986). "Application of organometallic catalysis to the commercial production of L-DOPA". Journal of Chemical Education. 63 (3): 222. Bibcode: 1986JChEd..63..222K. doi: 10.1021/ed063p222.
  40. ^ Brilliant MH, Vaziri K, Connor TB, Schwartz SG, Carroll JJ, McCarty CA, et al. (March 2016). "Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration". The American Journal of Medicine. 129 (3): 292–8. doi: 10.1016/j.amjmed.2015.10.015. PMC  4841631. PMID  26524704.
  41. ^ Fujii Y, Shibuya T, Yasuda T (1991). "L-3,4-Dihydroxyphenylalanine as an Allelochemical Candidate from Mucuna pruriens (L.) DC. var. utilis". Agricultural and Biological Chemistry. 55 (2): 617–618. doi: 10.1080/00021369.1991.10870627.
  42. ^ Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023). "L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner". Botanical Studies. 64 (24): 617–618. Bibcode: 2023BotSt..64...24H. doi: 10.1186/s40529-023-00396-7. PMC  10449704. PMID  37620733.

External links

  • "Levodopa". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from " https://en.wikipedia.org/?title=L-DOPA&oldid=1216844283"